The present invention discloses a novel polypeptide-human SR splicing factor
52 and polynucleotide encoding the same, as well as a method of producing the polypeptide
by DNA recombinant technology. The present invention also discloses methods of
using the polypeptide in treatment of various disease, such as malignant tumor,
blood disease, HIV infection, immunological disease and various inflammation. The
present invention also discloses an antagonist againts the polypeptide and the
therapeutic use of the same. The present invention also discloses the use of such
polynucleotide encoding Human SR splicing factor 52.
